A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea (OSA)
研究单位：[1]Ignis Therapeutics (Suzhou) Limited[2]Shanghai Sixth People''s Hospital,ShangHai,Shanghai,China[3]Beijing TianTan Hospital Capital Medical University,Beijing,China[4]China-Japan friendship Hospital,Beijing,China[5]Peking University Sixth Hospital,Beijing,China[6]XuanWu Hospital Capital Medical University,Beijing,China[7]The first hospital of Jilin University,Changchun,China[8]Xiangya Hospital Central South University,Changsha,China[9]ChongQing University three gorges Hospital,Chongqing,China[10]The Hospital Group of the First Affiliated Hospital of CQMU,Chongqing,China[11]GanSU Provincial Hospital,Gansu,China[12]The first affiliated hospital of Guangzhou Medical University,Guangzhou,China[13]The first affiliated hospital of JiNan University,Guangzhou,China[14]Hangzhou seventh People''s Hospital,Hangzhou,China[15]The first hospital of Hebei Medical University,Hebei,China[16]Huai''an First People''s Hospital,Huai''an,China[17]The Second Affiliated Hospital of Nanchang University,Nanchang,China[18]The Fitst Affiliated Hospital of NingBo University,Ningbo,China[19]ShanDong Provincial QianFoShan Hospital,Shandong,China[20]HuaShan Hospital FuDan University,Shanghai,China[21]First hospital of ShanXi Medical University,Shanxi,China[22]Second hospital of Shanxi Medical University,Shanxi,China[23]ShenZhen People''s Hospital,Shenzhen,China[24]West China fourth Hospital Sichuan University,Sichuan,China[25]The Second Affiliated Hospital of Suzhou University,Suzhou,China[26]Yan''an University Xianyang Hospital,Xianyang,China[27]The First People''s Hospital of YunNan Province,Yunnan,China
研究目的：
The purpose of this study is to evaluate the efficacy and safety of 12-week solriamfetol administration in the treatment of EDS in patients with OSA from China, using a randomized, double-blind, placebo-controlled, multi-center, parallel-design.
